• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2024 年,欧洲的胃癌筛查进展如何?

Where are we with gastric cancer screening in Europe in 2024?

机构信息

Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia

Department of Gastroenterology, Digestive Diseases Centre GASTRO, Riga, Latvia.

出版信息

Gut. 2024 Nov 11;73(12):2074-2082. doi: 10.1136/gutjnl-2024-332705.

DOI:10.1136/gutjnl-2024-332705
PMID:39237127
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11671906/
Abstract

The absolute number of annual cases of gastric cancer in Europe is rising. The Council of the European Union has recommended implementation of gastric cancer screening for countries or regions with a high gastric cancer incidence and death rates. However, as of 2024 no organised gastric cancer screening programme has been launched in Europe.There are several ways to decrease gastric cancer burden, but the for ) seems to be the most appropriate for Europe. It has to be noted that increased use of antibiotics would be associated with this strategy.Only organised population-based cancer screening is recommended in the European Union, therefore gastric cancer screening also is expected to fulfil the criteria of an organised screening programme. In this respect, several aspects of screening organisation need to be considered before full implementation of gastric cancer prevention in Europe; the age range of the target group, test types, eradication regimens and surveillance strategies are among them. Currently, ongoing projects (GISTAR, EUROHELICAN, TOGAS and EUCanScreen) are expected to provide the missing evidence. Feedback from the decision-makers and the potential target groups, including vulnerable populations, will be important to planning the programme.This paper provides an overview of the recent decisions of the European authorities, the progress towards gastric cancer implementation in Europe and expected challenges. Finally, a potential algorithm for gastric cancer screening in Europe is proposed.

摘要

欧洲每年胃癌的绝对病例数正在上升。欧盟理事会建议对胃癌发病率和死亡率高的国家或地区实施胃癌筛查。然而,截至 2024 年,欧洲尚未启动有组织的胃癌筛查计划。有几种方法可以降低胃癌负担,但在欧洲,似乎(根除)是最合适的方法。需要注意的是,这种策略的实施可能会伴随着抗生素使用的增加。欧盟仅推荐有组织的基于人群的癌症筛查,因此胃癌筛查也有望符合有组织筛查计划的标准。在这方面,在欧洲全面实施胃癌预防之前,需要考虑筛查组织的几个方面;其中包括目标人群的年龄范围、检测类型、(根除)方案和监测策略。目前,正在进行的项目(GISTAR、EUROHELICAN、TOGAS 和 EUCanScreen)有望提供缺失的证据。决策者和潜在目标群体(包括弱势群体)的反馈对于规划该计划至关重要。本文概述了欧洲当局的最新决定、在欧洲实施胃癌筛查的进展以及预期的挑战。最后,提出了一种在欧洲进行胃癌筛查的潜在算法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f34/11671906/84a5bafb3e4a/gutjnl-73-12-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f34/11671906/cf937d424892/gutjnl-73-12-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f34/11671906/84a5bafb3e4a/gutjnl-73-12-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f34/11671906/cf937d424892/gutjnl-73-12-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f34/11671906/84a5bafb3e4a/gutjnl-73-12-g002.jpg

相似文献

1
Where are we with gastric cancer screening in Europe in 2024?2024 年,欧洲的胃癌筛查进展如何?
Gut. 2024 Nov 11;73(12):2074-2082. doi: 10.1136/gutjnl-2024-332705.
2
AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review.美国胃癌高危个体筛查与监测的美国胃肠病学会临床实践更新:专家综述
Gastroenterology. 2025 Feb;168(2):405-416.e1. doi: 10.1053/j.gastro.2024.11.001. Epub 2024 Dec 23.
3
Screening and eradication of for gastric cancer prevention: the Taipei global consensus.胃癌预防的筛查和根除:台北全球共识。
Gut. 2020 Dec;69(12):2093-2112. doi: 10.1136/gutjnl-2020-322368. Epub 2020 Oct 1.
4
Asia-Pacific consensus guidelines on gastric cancer prevention.《亚太地区胃癌预防共识指南》
J Gastroenterol Hepatol. 2008 Mar;23(3):351-65. doi: 10.1111/j.1440-1746.2008.05314.x.
5
Screening for Helicobacter pylori to Prevent Gastric Cancer: A Pragmatic Randomized Clinical Trial.筛查幽门螺杆菌预防胃癌:一项实用随机临床试验。
JAMA. 2024 Nov 19;332(19):1642-1651. doi: 10.1001/jama.2024.14887.
6
Multicentric randomised study of eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study.根除幽门螺杆菌及胃蛋白酶原检测预防胃癌死亡的多中心随机研究:GISTAR研究
BMJ Open. 2017 Aug 11;7(8):e016999. doi: 10.1136/bmjopen-2017-016999.
7
Clinical aspects of gastric cancer and Helicobacter pylori--screening, prevention, and treatment.胃癌和幽门螺杆菌的临床方面——筛查、预防和治疗。
Helicobacter. 2010 Sep;15 Suppl 1:40-5. doi: 10.1111/j.1523-5378.2010.00783.x.
8
Population based Helicobacter pylori screening and eradication: advances versus side effects.基于人群的幽门螺杆菌筛查与根除:进展与副作用
Curr Pharm Des. 2014;20(28):4501-9. doi: 10.2174/13816128113196660733.
9
Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan.在日本,通过根除幽门螺杆菌和连续监测来消除胃癌的路线图。
J Gastroenterol. 2014 Jan;49(1):1-8. doi: 10.1007/s00535-013-0897-8. Epub 2013 Oct 27.
10
Should we screen for Helicobacter pylori to prevent gastric cancer?我们应该筛查幽门螺杆菌以预防胃癌吗?
Dig Dis. 2007;25(3):218-21. doi: 10.1159/000103888.

引用本文的文献

1
The Prevalence of Gastric Atrophy in Western and Northern European Populations: A Systematic Review and Meta-Analysis.西欧和北欧人群中胃萎缩的患病率:一项系统评价和荟萃分析。
J Gastrointest Cancer. 2025 Aug 19;56(1):174. doi: 10.1007/s12029-025-01291-z.
2
Helicobacter pylori Infection in Children Versus Adults, Differences in Management Guidelines: Risks and Benefits of Treatment in Childhood.儿童与成人幽门螺杆菌感染:管理指南的差异——儿童治疗的风险与益处
Helicobacter. 2025 Jul-Aug;30(4):e70063. doi: 10.1111/hel.70063.
3
Global trends and sociodemographic inequalities in smoking and high-salt diet attributable to gastric cancer: a secondary analysis based on the global burden of disease 2021 study.

本文引用的文献

1
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
2
Population-level cancer screening and cancer care in Bhutan, 2020-2023: a review.不丹2020 - 2023年的人群层面癌症筛查与癌症护理:综述
Lancet Reg Health Southeast Asia. 2024 Feb 28;24:100370. doi: 10.1016/j.lansea.2024.100370. eCollection 2024 May.
3
RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates.
归因于胃癌的吸烟和高盐饮食的全球趋势及社会人口学不平等:基于2021年全球疾病负担研究的二次分析
BMC Cancer. 2025 Jul 30;25(1):1248. doi: 10.1186/s12885-025-14605-y.
4
[High PRELID1 expression promotes epithelial-mesenchymal transition in gastric cancer cells and is associated with poor prognosis].[高PRELID1表达促进胃癌细胞上皮-间质转化并与不良预后相关]
Nan Fang Yi Ke Da Xue Xue Bao. 2025 Jul 20;45(7):1535-1542. doi: 10.12122/j.issn.1673-4254.2025.07.21.
5
Risk factors for gastric cancer: an umbrella review of systematic reviews and meta-analyses.胃癌的危险因素:系统评价和荟萃分析的伞状综述
Front Oncol. 2025 Jun 26;15:1564575. doi: 10.3389/fonc.2025.1564575. eCollection 2025.
6
Global lifetime estimates of expected and preventable gastric cancers across 185 countries.185个国家胃癌预期发病数和可预防发病数的全球终生估计。
Nat Med. 2025 Jul 7. doi: 10.1038/s41591-025-03793-6.
7
Validation of the ABC Method for Gastric Cancer Risk Stratification Across Helicobacter pylori Infections With Diverse CagA Status and Subtypes in Brazil.巴西针对幽门螺杆菌不同CagA状态和亚型感染的胃癌风险分层ABC方法的验证
Cancer Med. 2025 Jul;14(13):e71016. doi: 10.1002/cam4.71016.
8
Seroprevalence and Its Associations with Sociodemographic Characteristics, Environmental Factors, and Gastrointestinal Complaints: A Cross-Sectional Study in the Adult Population of Kaunas City, Lithuania.血清阳性率及其与社会人口学特征、环境因素和胃肠道不适的关联:立陶宛考纳斯市成年人口的横断面研究
Medicina (Kaunas). 2025 Jun 6;61(6):1049. doi: 10.3390/medicina61061049.
9
Identification of Anoikis-Related Genes in Gastric Cancer: Bioinformatics and Experimental Validation.胃癌中失巢凋亡相关基因的鉴定:生物信息学及实验验证
Cancer Med. 2025 Apr;14(8):e70907. doi: 10.1002/cam4.70907.
10
Gastric Adenocarcinomas with CDX2 Induction Show Higher Frequency of and Mutations and Amplifications but Similar Survival Compared with Cancers with No CDX2 Induction.与未诱导CDX2的癌症相比,诱导CDX2的胃腺癌显示出更高频率的 和 突变以及 扩增,但生存率相似。 (你提供的原文中存在部分未明确的内容,如“ 和 ”处,以上是根据现有完整部分的翻译)
J Clin Med. 2024 Dec 15;13(24):7635. doi: 10.3390/jcm13247635.
RE.GA.IN.:真实世界胃炎倡议——更新再更新
Gut. 2024 Feb 23;73(3):407-441. doi: 10.1136/gutjnl-2023-331164.
4
Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022.1980年至2022年间幽门螺杆菌感染的全球流行率及胃癌发病率
Gastroenterology. 2024 Apr;166(4):605-619. doi: 10.1053/j.gastro.2023.12.022. Epub 2024 Jan 2.
5
Clarithromycin-containing triple therapy for eradication is inducing increased long-term resistant bacteria communities in the gut.含克拉霉素的三联疗法用于根除幽门螺杆菌正在导致肠道中长期耐药细菌群落增加。 (注:原文未提及“幽门螺杆菌”,但根据医学常识推测此处应该是指根除幽门螺杆菌,如不是此语境请根据实际情况调整)
Gut. 2024 Jun 6;73(7):1214-1215. doi: 10.1136/gutjnl-2023-329792.
6
Recent Mortality Patterns and Time Trends for the Major Cancers in 47 Countries Worldwide.全球 47 个国家主要癌症的近期死亡率模式和时间趋势。
Cancer Epidemiol Biomarkers Prev. 2023 Jul 5;32(7):894-905. doi: 10.1158/1055-9965.EPI-22-1133.
7
Assessing the utility of pepsinogens and gastrin-17 in gastric cancer detection.评估胃蛋白酶原和胃泌素-17 在胃癌检测中的应用。
Eur J Cancer Prev. 2023 Sep 1;32(5):478-484. doi: 10.1097/CEJ.0000000000000791. Epub 2023 Mar 13.
8
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.二线左氧氟沙星为基础的四联疗法与铋剂四联疗法根除幽门螺杆菌及对肠道微生物群和抗生素耐药组的长期影响:一项多中心、开放标签、随机对照试验。
Lancet Gastroenterol Hepatol. 2023 Mar;8(3):228-241. doi: 10.1016/S2468-1253(22)00384-3. Epub 2022 Dec 19.
9
Gastric Cancer Screening in Japan: A Narrative Review.日本的胃癌筛查:一篇叙述性综述。
J Clin Med. 2022 Jul 26;11(15):4337. doi: 10.3390/jcm11154337.
10
Assessment of Serum Pepsinogens with and without Co-Testing with Gastrin-17 in Gastric Cancer Risk Assessment-Results from the GISTAR Pilot Study.在胃癌风险评估中联合或不联合胃泌素-17检测血清胃蛋白酶原的评估——GISTAR试点研究结果
Diagnostics (Basel). 2022 Jul 19;12(7):1746. doi: 10.3390/diagnostics12071746.